Policy & Geopolitics
Aquestive's Anaphylm FDA Rejection Validates Core Science—Stock Surges 40% After Hours
2d ago
You're signed outSign in or to get full access.
AT
Aquestive Therapeutics (AQST)·Earnings Reports
Q3 2025
View earnings summary and analysis
Q2 2025
View earnings summary and analysis
Q1 2025
View earnings summary and analysis
Q4 2024
View earnings summary and analysis
Research analysts covering Aquestive Therapeutics.